NCT06662721 is a Phase 2 clinical trial of Baricitinib 4 MG in Takayasu Arteritis, sponsored by Liu Tian.

Who is sponsoring NCT06662721?

NCT06662721 is sponsored by Liu Tian.

What drugs are being tested in NCT06662721?

Interventions in NCT06662721: Baricitinib 4 MG.

What condition does NCT06662721 study?

NCT06662721 studies Takayasu Arteritis.

Is NCT06662721 still recruiting?

NCT06662721 is currently completed. Last updated 29 October 2024.

Last reviewed 2024-10-29 · How we verify

NCT06662721

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Baricitinib for Refractory Takayasu Arteritis

Completed Phase 2 Last updated 29 October 2024

What this trial tests

Phase 2 trial testing Baricitinib 4 MG in Takayasu Arteritis in 10 participants. Completed in 8 June 2024.

Timeline

3 April 2023

Primary endpoint
23 December 2023

8 June 2024

Quick facts

Lead sponsor	Liu Tian
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	10
Start date	3 April 2023
Primary completion	23 December 2023
Estimated completion	8 June 2024
Sites	1 location across China

Drugs / interventions tested

Baricitinib 4 MG — full drug profile →

Conditions studied

Takayasu Arteritis — all drugs for Takayasu Arteritis →

Sponsor

Liu Tian

Who can join

Adults 18 to 70, any sex, with Takayasu Arteritis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Takayasu arteritis (TKA) is an autoimmune vasculitis characterized with involvement of aorta and its primary branches. For TKA refractory to TNF-α, Baricitinib, a reversible inhibitor of Janus kinases (JAK) family members JKA1 and JAK2, represents a potential treatment option. This study aims to assess the efficacy and safety of Baricitinib in TKA refractory to TNF-α inhibitors.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Baricitinib for Takayasu arteritis refractory to TNF-α inhibitors: a multicentre, single-arm trial.
Li J, Xia W, Ji H, Gong X, et al · · 2025 · PMID 40411764 · DOI 10.1093/rheumatology/keaf286

Verify or expand the search:

Other trials of Baricitinib 4 MG

Trials testing the same drug.

NCT05858515 — REVERSE-Long COVID-19 With Baricitinib Study · Phase 3 · withdrawn
NCT06439615 — Baricitinib for the Lung Injury Following Spontaneous SAH · Phase 2 · not yet recruiting
NCT06065046 — Baricitinib for Moderate and Severe Traumatic Intracerebral Hemorrhage/Contusions · Phase 2 · recruiting
NCT05969730 — Baricitinib Versus Azathioprine in Patients With Moderate-to-Severe Atopic Dermatitis · NA · completed
NCT05914584 — "Baricitinib for Treating Hospital-acquired Pneumonia in Critically Ill Patients With a Proinflammatory Phenotype. · Phase 2, PHASE3 · unknown

Other recruiting trials for Takayasu Arteritis

Currently open trials in the same condition.

NCT07087912 — Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases · Phase 4 · recruiting
NCT07351422 — Investigating Management, Perspectives and Attitudes Towards Care in Takayasu Arteritis · recruiting
NCT07276087 — Physical and Psychosocial Parameters in Takayasu Arteritis and Behçet's Disease: A Comparative Study With Healthy Contro · recruiting
NCT07491913 — Biologic Treatment Withdrawal in Takayasu Arteritis Patients in Sustained Remission · NA · recruiting
NCT06887062 — Dapagliflozin and Endothelin Receptor Antagonism in Large Vessel Vasculitis (DERAIL-LVV) · Phase 2 · recruiting

Other Liu Tian trials

Trials by the same sponsor.

NCT07500467 — Upadacitinib for Refractory Takayasu Arteritis · completed
NCT07080346 — Upadacitinib for Refractory Behcet's Syndrome · Phase 2 · completed
NCT05339217 — Efficacy and Immunological Evaluation of Telitacicept and Low Dose IL2 in the Treatment of Systemic Lupus Erythematosus · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06662721 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Liu Tian
Last refreshed: 29 October 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06662721.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing